Abstract a-globin is encoded by two adjacent genes, al and a2. Recent evidence suggests that these genes are not equally expressed and that the a2-globin gene encodes the majority of a-globin. This finding would predict that a thalassemic mutation of the a2-globin gene would result in a more severe loss of a-chain synthesis than a similar mutation in the al-globin gene. In a previous study we described a nondeletion a-thalassemia defect in the a2-globin gene resulting from an AUG --ACG initiation codon mutation. In the present study we describe a different initiation codon mutation, AUG -GUG, present in the al-globin gene. The al-and a2-globin gene initiation codon mutations result in similarly lowered levels of encoded mRNA. Despite the similarity of these two mutations, the a2 mutant results in a more severe loss of a-globin synthesis and a more severe clinical a-thalassemia phenotype than the corresponding al-globin gene mutation. This difference reflects the dominant role of a2-globin gene in overall a-globin synthesis.
Introduction
The a-globin gene cluster is located on the short arm of chromosome 16 (1) . The genes in this cluster are arranged in the order 5'-t-4.-a-a2-a 1-3' (2-3). A variety of mutations within this cluster result in deficient or absent synthesis of a-globin and the consequent group of genetic disorders known as the a-thalassemias (4) . Most commonly, a-thalassemia results from the deletion of one or both of the a-globin genes (5) . Less commonly, a-globin gene function is altered by a defect that does not produce a gross gene deletion (6) (7) (8) . Several such nondeletion a-thalassemias have now been defined at a molecular level. These include: termination codon mutations such as Hb Constant Spring (9), a splicing defect caused by a 5-basepair (bp) deletion of the first intervening sequence (10) , Hb Quong Sze, an extremely unstable a-globin structural variant (1 1, 12), a single nucleotide substitution of the polyadenylation site ( 1 3), a two nucleotide deletion at position -1 and -2 in the 5' untranslated region preceding the AUG codon (14) , an initiation codon mutation (AUG --ACG) (15) and a nonsense mutation (a 116 GAG --UAG) (16) . Apart from the -1, -2 deletion that occurs in a single a-globin gene chromosome, each of these mutations affects the a2-globin gene.
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Hemoglobin H (HbH)' disease, the most severe form of a-thalassemia compatible with life, commonly results from the deletion of three of the four a-globin genes (17) (18) (19) (20) (21) (22) (23) . Less commonly, HbH disease can also result from the deletion of the two a-globin genes on one chromosome combined with a nondeletion defect affecting one of the two a-globin genes on the other chromosome. In Sardinians, the most common nondeletion a-thalassemia defect is the AUG --ACG mutation in the initiation codon of the a2-globin gene (15, (24) (25) (26) (34) . The labeled protein products were resolved on a Triton-acid-urea slab gel (35, 36) and visualized by autoradiography. The ratio of a2-to a I -globin mRNA was established by primer extension analysis as previously detailed (33) with the following exception: we have substituted for the previously described 31 nucleotide cDNA primer, a 20 nucleotide synthetic oligonucleotide (3'-CACCCGCCGT--1---11Fil---1--5') that is complementary to the terminal 9 nucleotides of both a. I-and a2-globin mRNAs and to 11 adenosines of the contiguous poly-A tail. This oligomer was 5' end-labeled with -4(32P)ATP (5, (Fig. 2) .
The 4.8 and 3.7 fragments contain the al-and the a2-globin genes, respectively. The 2. 1-kb fragment spans from the initiation codon ofthe a2-globin gene to a NcoI site located in the 5' flanking region. DNA from the patients investigated (111-2 and 111-3) yielded the normal 2.1-kb fragment associated with a new 8.5-kb fragment that replaces the normal 3.7-and 4.8-kb fragments (Fig. 2) . This pattern suggests the loss of the NcoI restriction site located in the a I-globin gene. This interpretation was confirmed by double digestion ofthe DNA with NcoI and HindIII (data not shown). These findings indicate that our patient has a mutation in the a 1-globin gene that abolishes the NcoI site normally located in the 5' part of the gene. NcoI digestion of DNA isolated form the father and paternal grandmother yielded the 8.5-kb abnormal fragment in addition to the normal 4.8-, 3.7-, and 2.1-kb fragments which indicated the presence ofthe nondeletion defect in one chromosome and a normal a-globin gene complement in the other chromosome. A summary of the a-thalassemia inheritance in this family is presented in Fig. 1 (37) . To determine the exact nature of the a 1-globin gene mutation that destroys the NcoI site, the (Fig. 3 ). mRNA analysis. The relative levels of al-and a2-globin mRNA in total reticulocyte RNA was measured by primer extension mapping. The results of studies on a normal aa/aa, a previously reported --/aTha individual, and one of the --a/aaTh individuals (III-2) are shown in Fig. 4 . In normal reticulocytes the a2:al mRNA ratio is 2.6 (33, 38). In four unrelated Sardinian patients with nondeletion hemoglobin H disease in whom the nondeletion defect was the T --C substitution in the ATG initiation codon of the a2 gene (--/cTha) the average ratio was 0.9 (range 0.75-1.3) indicating that the level of steady state a2-globin mRNA was decreased to approximately one-third of its normal level (Fig. 4 and Table II ). This value is consistent with the previously reported value of 1.0 (15). In the two sisters III-2 and 111-3 with the ATG GTG mutation in the al-globin gene (--/aaTh) the ao2/al ratios of 12 and 14, respectively, indicated a reduction in the steady-state level of a 1 mRNA to approximately one-fourth of its normal level.
In vitro translation. Unfractionated mRNA was translated in vitro and the labeled translation products were resolved and quantitated by electrophoresis and densitometry. The results of this analysis are shown in Fig. 5 and summarized in Table II. In vitro translation of normal reticulocyte mRNA gives an a/l3 globin synthesis ratio (corrected for methionine content of two in a and one in ,) of 1.5 while in four unrelated individuals with HbH disease and the nondeletion (ATG -> ACG) defect in the a2-globin gene (--/aTha) had an average ratio of 0.095 (range 0.04-0.16; Table II ). The afl3 globin ratios of111-2 and III-3 (--/aaTh) were 0.22 and 0.27, respectively. In a parallel set ofexperiments a/(3 synthesis was measured in intact reticulocytes from each ofthese individuals. As the a2 mutation (--/aTba). The uniformly lower a/fl ratios measured by in vitro translation as compared to the reticulocyte incubations may reflect the ability of proteolytic systems in the intact cell to partially compensate for the chain imbalance. Such discrepancies between the al/( synthetic ratios obtained in vitro and during the labeling of intact reticulocytes are observed in a wide variety of deletion and nondeletion a-thalassemias (S. A. Liebhaber and F. E. Cash, unpublished data).
Discussion
In this study we have characterized a newly discovered mutation, ATG --GTG, in the initiation codon of the al-globin The severity of the a-thalassemia phenotype appears to relate both to the specific a-globin gene lost (a 1 or a2) and the manner in which it is lost (deletion versus nondeletion). a-globin production during in vitro translation of reticulocyte RNA and during labeling of intact reticulocytes was less significantly depressed in the --IaaTh patients (III-2 and 111-3), than in the patients with a similar initiation codon mutation in the a2-globin gene (-_/aTha) ( Fig. 5 and Table II ). The mild phenotype noted in these two patients with the --l/aa genotype is very similar to that manifested by patients with the deletional form of HbH disease (--I-a), and is significantly less severe than patients with HbH disease resulting from nondeletion defects (ATG ACG, Hb Constant Spring) in the a2 gene (25, 42, 43) . Since the a2-globin gene normally encodes twoto threefold higher steady state level of mRNA (33, 38, 44 ) and produces two-to threefold more a-globin (45, 46) than the al-globin gene, a nondeletion defect in the a2-globin gene would be expected to result in the loss of two to three times more a-globin synthesis than a comparable mutation in the a 1 gene. The rightward type a-thalassemia deletion (-aC3 7) would be predicted to yield a mild phenotype comparable to an a1 nondeletion mutation since the loss of the a2-globin gene is associated with a 1.8-fold compensatory increase in the expression of the remaining al-globin gene (38) .
The initiation codon mutation described herein is the first a-thalassemia mutation to date identified in the a I-globin gene; the previously reported frameshift in the a 1-globin gene associated in Cis to a polyadenylation signal mutation of the a2-globin gene is now demonstrated to be a cloning artifact (personal communication, D. Higgs). All previously defined nondeletion a-thalassemia mutations are at the a2 locus or on single ac-globin gene chromosomes. This asymmetry in the distribution of a-globin gene nondeletion defects cannot be attributed to unequal mutation rates of two a-globin genes since nonthalassemic a-globin structural mutations are equally distributed between these two loci (46) . Instead this distribution probably reflects an ascertainment bias due to the greater impact ofa2 mutations upon a-globin synthesis (46) . It is therefore entirely reasonable to assume that an equal number of thalassemia mutations of the a 1 locus exist but remain phenotypically silent due to the minimal loss of the total aglobin synthetic capacity. It is only when the a 1 mutation is associated with other a-thalassemic mutations in the genome that the small incremental loss of a 1 -globin gene function can be appreciated.
